Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
Laboratorios Ojer Pharma, S.L.
Laboratorios Ojer Pharma, S.L.
 
Type
PYME
Private entity
Contact
Marta Muntión Sáenz. Business Development Manager
Province: Navarra
Phone: 34 948287859
Mobile Phone: 34 638062607
Fax: 34 948281776
mmuntion@ojerpharma.com
http://www.ojerpharma.com
Activity
Ojer Pharma is a spin-off company of the University of Navarra that aims at developing a pipeline of innovative dermatological medicines with a national and international scope. Due to its tight collaboration with prestigious research centres from the public and the private sector (such as the Center for Applied Pharmacobiology Research (CIFA) and the University Hospital of the University of Navarra (CUN), together with the Service of Development of Medicines (SDM) of the University of Barcelona), the company has direct access to cutting edge findings in medicine, which allows us to provide our clients with more effective dermatological solutions.
Ojer Pharma’s portfolio consists of a wide set of innovative medicines with proven safety and efficacy for common dermatological diseases (Rx & OTC). The aim of our products is to fulfill those therapeutic gaps that conventional treatments fail to achieve, through the simultaneous treatment of aetiological and symptomatological aspects of skin conditions, which reduces both illness permanence and polymedication.
The company is internationally oriented as it aims at commercializing its products in multiple countries, mainly in Europe, Latin America, US and some Asian nations. In order to achieve that, our laboratory seeks for partners interested in co-developing our dermatological drugs and willing to in-license our products.
Projects
INDERMA 2007-2010 Project: Development of the dermatological products OJER-P10 and OJER-P20. Project funded by the Center for Industrial Technological Development (CDTI). Ministry of Science and Innovation. Spain
Study CIFA 005/08: Study of dermal tolerance of OJER-P10 in rabbits. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 006/08: Toxicity study following repeated dermal administration of OJER-P10 in rabbits. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 014/09: Study of OJER-P20 in vitro antimicrobial activity. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 013/09: Development and validation of a murine infection model. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 017/10: Study of local tolerance following repeated dermal administration of OJER-P10 in rabbits. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 018/10: Study of toxicity following repeated dermal administration of OJER-P20 in rabbits. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 019/10: Study of acute dermal irritation/corrosion following local administration of OJER-P20 in rabbits. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Study CIFA 019/10: Study of acute eye irritation/corrosion following local administration of OJER-P20 in rabbits. Project developed in collaboration with the Center for Applied Research Pharmacobiology (CIFA), University of Navarra. Spain
Permalink: http://www.mercadosbiotecnologicos.com/?eid=113&etid=1&lan=en

Search